Foundation Medicine says genomic profiling assay now available in U.S.
Foundation Medicine announced that FoundationOne CDx, the first FDA approved comprehensive genomic profiling assay for all solid tumors incorporating multiple companion diagnostics, is now available in the United States. FoundationOne CDx assesses genomic alterations in 324 genes known to drive cancer growth. "Now that FoundationOne CDx is widely available in the U.S., oncologists can begin using this valuable test to help guide and simplify personalized treatment decisions for their patients," Vincent Miller, Chief Medical Officer at Foundation Medicine. "By integrating FoundationOne CDx early into routine clinical care, oncologists can create treatment efficiencies and expand access to biomarker-driven medicines for patients, with the potential to improve treatment outcomes."